The aim of the present study was to determine the frequency and clinical relevance of the most common secondary karyotype abnormalities in TEL/AML1 þ B-cell precursor acute lymphoblastic leukemia (ALL) as assessed with fluorescence in situ hybridization (FISH) analyses. Screening of 372 patients who were enrolled in two consecutive Austrian childhood ALL multicenter trials identified 94 (25%) TEL/AML1 þ cases. TEL deletions, trisomy 21 and an additional der(21)t(12;21) were detected in 52 (55%), 13 (14%) and 14 (15%) TEL/AML1 þ patients, respectively. The 12p aberrations (P ¼ 0.001) and near tetraploidy (P ¼ 0.045) were more common in TEL/AML1 þ patients, whereas the incidence of diploidy, pseudodiploidy, hypodiploidy, low hyperdiploidy, near triploidy, del(6q), chromosome 9 and 11q23 abnormalities was similar among TEL/ AML1 þ and TEL/AML1À patients. None of the TEL/AML1 þ patients had a high hyperdiploid karyotype. Univariate analysis indicated that among TEL/AML1 þ patients those with a deletion of the nontranslocated TEL allele had a worse prognosis than those without this abnormality (P ¼ 0.034). We concluded that the type and incidence of the most common secondary aberrations in TEL/AML1 þ ALL can be conveniently identified with little additional effort during interphase screening with appropriate TEL and AML1 FISH probes. We also provided preliminary evidence that the deletion of the nontranslocated TEL allele may adversely influence the clinical course of TEL/AML1 þ ALL.
Introduction
With an incidence of 20-25%, the translocation t(12;21)(p13;q22) and its molecular genetic counterpart, the TEL/AML1 fusion gene, is the most common specific genetic rearrangement in childhood acute lymphoblastic leukemia (ALL). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Based on event-free survival (EFS) rates between 90 and 100%, it was originally believed that this rearrangement is a rather favorable prognostic indicator in B-cell precursor (BCP) ALL. [3] [4] [5] [6] [8] [9] [10] [11] [12] [13] However, this notion was subsequently disputed by others as they found a similar incidence of TEL/AML1 þ cases at initial diagnosis and relapse. 7, 9, 14, 15 Since the median onset of TEL/AML1 þ relapses occurs comparatively late, some of the discrepant incidence rates of relapses in TEL/AML1 þ leukemia may result from different sample sizes and clinical follow-up times. 7, 9, [13] [14] [15] [16] [17] Although some of them are probably also due to differences in the respective treatment regimens, at present no parameters except for molecular response kinetics are well established, which could help to predict which patients are most likely to relapse. 7, 9, [12] [13] [14] [15] [16] [17] [18] The results of sophisticated molecular genetic studies, particularly those in twins and triplets together with retrospective analyses of Guthrie cards from patients with a TEL/ AML1 þ ALL, imply that the TEL/AML1 fusion gene may be one of the initiating events in the malignant transformation process. 19, 20 Nevertheless, they also support the notion that additional mutations are necessary to trigger the development to overt leukemia. Some of these events could be reflected on the chromosomal level as nonrandom secondary abnormalities and comprise, in particular, the deletion of the nonrearranged TEL allele, the duplications of the normal chromosome 21 and the der(21)t(12;21) as well as more unspecific ones such as 6q deletions and 9p abnormalities. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Since the t(12;21) is virtually undetectable with conventional cytogenetic procedures, the two preferred screening methods are those with reverse transcriptase polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH). 1-6, 9-13,17,21-33 The latter technology has the advantage that it enables the identification and quantification of the most common and, thus, most relevant secondary changes on a single cell level. The aim of our retrospective study was therefore to determine these parameters in a large series of unselected childhood ALL patients who were enrolled in two consecutive Austrian multicenter trials and to evaluate their potential biological and prognostic relevance.
Patients and methods

Patients
Between April 1990 and July 1999, 486 previously untreated Austrian children and adolescents up to 18 years of age with ALL were enrolled in two consecutive multicenter trials of the Berlin-Frankfurt-Mü nster (BFM) group: ALL-BFM-A (Austria) 1990 (n ¼ 256) and ALL-BFM-A 1995 (n ¼ 230). ALL was diagnosed according to standard morphological, cytochemical and immunological criteria. 34 All cases were reviewed by the study center and the patients were treated according to the respective BFM therapy protocols after informed consent was obtained from either the patient's parents or legal guardians. Treatment stratification and protocols used in trials BFM-A 90 and BFM-A 95 have been published previously and response criteria as well as definition of relapse have been described in detail elsewhere. 35, 36 Of the 486 patients, 428 (88%) had a BCP ALL and 58 (12%) a T-cell ALL. The latter were excluded from our analysis, because the TEL/AML1 rearrangement occurs exclusively in patients with BCP ALL. All 372 patients (87%) with BCP ALL, for whom adequate bone marrow (BM) samples were available, were examined with FISH. The distribution of sex, French-AmericanBritish (FAB) classification, central nervous system (CNS) and gonadal involvement in this group of patients was comparable with that of the 56 BCP cases (13%) that could not be analyzed. Although the frequency of patients with a high initial white blood cell (WBC) count (X20 000/ml, Po0.001; X50 .000/ml, Po0.001) and an age over 10 years (P ¼ 0.018) was significantly higher in the screened group, the frequency of prednisone poor responders (P ¼ 0.175) and patients with high-risk (HR) criteria (P ¼ 0.167) as well as the probability of EFS (pEFS) at 5 years (8072 vs 8775%; P ¼ 0.290) were not significantly different from that of the patients in the nonscreened group.
Cytogenetic and FISH analyses
Cytogenetic analyses of trypsin/Giemsa-banded BM preparations were performed centrally according to standard procedures. Interphase FISH analyses were also carried out centrally at the national study center by one observer and positive results were double-checked by a second observer. The commercial dual color-labeled LSI TEL/AML1 ES probe set (Vysis, Downers Grove, IL, USA) was used according to the manufacturer's recommendation on methanol/acetic acid fixed cell samples that had been cultured for 24 h and stored at À201C. This probe set consists of a SpectrumGreen-labeled TEL probe that begins between exons 3 and 5 and extends approximately 350 kb towards the telomere of chromosome 12 and a SpectrumOrange-labeled, approximately 500 kb long AML1 probe that spans the entire gene. In order to exclude any misinterpretations, we also double-checked all cases with a potential extra chromosome 21 with a chromosome 21-specific subtelomere probe (Vysis, Downers Grove, IL, USA). At least 200 nuclei per sample were screened with each probe. A sample was considered positive, if at least 10% of nuclei revealed a particular abnormality pattern. The interphase FISH results were confirmed by metaphase analyses in all cases with available material.
Statistical analyses
EFS and overall survival (SU) rates were analyzed according to the Kaplan-Meier method and survival curves were compared by means of the log-rank test. EFS was defined as the time from diagnosis to the first adverse event or to the date of last followup. Failure to achieve remission (early death, refractory disease), relapse at any site, and death during CR, or the development of a second malignancy were considered to be adverse events. Patients who failed to achieve CR were assigned to a failure time of zero. Overall survival was defined as the time from diagnosis to death from any cause, and for surviving patients, SU was censored at the date of last follow-up. Rank-order comparisons of the prognostic relevance of different parameters were examined by stepwise Cox's regression analysis. Differences in presenting clinical and biological characteristics at the time of diagnosis were analyzed by Fisher's exact test. P-values p0.05 are referred to as statistically significant.
Results
Characteristics and outcome of the TEL/AML1 þ and TEL/AML1À patients
The clinical and laboratory findings of the patients analyzed are summarized in Table 1 . With FISH, we identified a TEL/AML1 rearrangement in 94 (25%) of the 372 patients. (Although not included in our study, all 56 T-cell ALL patients analysed were TEL/AML1À.) Except for the following, the clinical and laboratory parameters were comparable between the TEL/ AML1 þ and TEL/AML1À groups: TEL/AML1 þ patients were more likely to be older than 1 year (P ¼ 0.021) and younger than 10 years of age (Po0.001), to have a FAB L1 morphology (P ¼ 0.034) and a common BCP phenotype (P ¼ 0.003) that frequently coexpressed one of the myeloid antigens CD13, CD33 or CDw65 (P ¼ 0.002).
Moreover, the proportion of TEL/AML1 þ cases was significantly higher among patients with a good prednisone response on day 8 (P ¼ 0.012), among patients with standard risk and medium risk criteria (P ¼ 0.001) and among patients with inbetween 5 and 25% blasts in BM (M2 BM) on day 15 (P ¼ 0.028). However, the frequency of patients with fewer than 5% blasts in BM on day 15 (M1 BM) was not statistically different between TEL/AML1 þ and TEL/AML1À patients (P ¼ 0.080). In all, 92 (98%) of 94 TEL/AML1 þ and 273 (98%) of 278 TEL/AML1À patients achieved a CR by day 33 (P ¼ 0.751).
Out of the 94 TEL/AML1 þ patients, nine (10%) had a relapse (one very early (11%), two early (22%) and six late (67%) relapses) and four patients (4%) died. The relapsed patients included six isolated and two combined BM relapses and one local disease recurrence in the ovary. In comparison, 54 (19%) of 278 TEL/AML1À patients experienced a relapse, including 20 (37%) very early, 13 (24%) early and 21 (39%) late disease recurrences. They comprised 32 isolated and 10 combined BM as well as seven isolated CNS and four isolated testicular The 5-year EFS estimates were 9074% for the TEL/AML1 þ patients and 7773% for the TEL/AML1À patients (P ¼ 0.003) after a median follow-up of 5.81 years (range 0.48-11.48 years). The probability of SU (pSU) at 5 years was also significantly different between the two groups of patients (9573 vs 8672%; P ¼ 0.005). TEL/AML1 þ patients still had a significantly better 5-year EFS, when those nine patients with a t(9;22), nine with a t(4;11) and 12 with a t(1;19) were excluded from analysis (9074 vs 7973%; P ¼ 0.009). The pEFS was also significantly better for the TEL/AML1 þ group if all HR patients (two TEL/AML1 þ and 38 TEL/AML1À patients) were excluded from analysis (9074 vs 8173%; P ¼ 0.022).
Besides TEL/AML1 negativity, in univariate analysis, high WBC counts at diagnosis (X50 000/ml; P ¼ 0.022) and age less than 1 year (P ¼ 0.001) were also associated with an increased risk of treatment failure. We performed a stepwise Cox's regression analysis to adjust the evaluation of the prognostic impact of the TEL/AML1 fusion gene on EFS by other parameters (sex, age, WBC count, study) and the results revealed that TEL/ AML1 positivity maintained its beneficial influence on prognosis (P ¼ 0.003). In this multivariate analysis, WBC count (P ¼ 0.023) at diagnosis was also an independent prognostic parameter.
The incidence of TEL/AML1 among the relapsed BCP ALL study population was nine of 63 (14%) and 16% among relapsed t(9;22)-, t(4;11)-and t(1;19)-negative BCP ALL patients.
Cytogenetic features of the TEL/AML1 þ and TEL/AML1À patients Cytogenetic data were available from 299 (80%) of the 372 patients, including 72/94 (77%) TEL/AML1 þ and 227/278 (82%) TEL/AML1À cases. The other 73 patients (20%) had no metaphases available. In none of the cytogenetic samples a t(12;21) was identified prior to FISH analysis. Numerical abnormalities were present in 26/72 (36%) TEL/AML1 þ and 107/227 (47%) TEL/AML1À patients (P ¼ 0.066). The frequency of diploid (26/72 (36%) vs 64/227 (28%)), hypodiploid (7/72 (10%) vs 10/227 (4%)), low hyperdiploid (10/72 (14%) vs 19/ 227 (8%)) and near triploid karyotypes (2/72 (3%) vs 4/227 (2%)) was similar in the two groups of patients (P40.05). However, high hyperdiploid karyotypes were only detected in the TEL/ AML1À group (0/72 vs 71/227 (31%); Po0.001), whereas three of four cases with a near tetraploid karyotype were TEL/AML1 þ (3/72 (4%) vs 1/227 (0.5%); P ¼ 0.045). The presence of tetraploid clones in these instances was confirmed with DNA content measurements. The prevalence of a constitutional trisomy 21 was similar among TEL/AML1 þ and TEL/AML1À ALL patients (2/72 (3%) vs 6/227 (3%); P ¼ 0.703).
Structural chromosomal changes were detected in 37/72 (51%) TEL/AML1 þ and 107/227 (47%) TEL/AML1À patients (P ¼ 0.311). Chromosome 12p abnormalities were significantly more common in TEL/AML1 þ than in TEL/AML1À patients (13/ 72 (18%) vs 11/227 (5%); P ¼ 0.001). The incidence of pseudodiploid karyotypes (22/72 (31%) vs 54/227 (24%)), 6q deletions (7/72 (10%) vs 10/227 (4%)) and 11q23 aberrations (3/ 72 (4%) vs 11/227 (5%)), as well as structural (9/72 (12.5%) vs 25/227 (11%); p-arm: 3 vs 16, q-arm: 5 vs 5, both arms: 1 vs 4) and numerical abnormalities involving chromosome 9 (3/72 (4%) vs 18/227 (8%); gain: 0 vs 9, loss: 3 vs 9) did not differ significantly between TEL/AML1 þ and TEL/AML1À patients (P40.05). Finally, the t(12;21) never concurred with a t(9;22), t(4;11) or t(1;19).
Interphase FISH of the TEL/AML1 þ and TEL/AML1À patients A TEL deletion was found significantly more often in the 94 TEL/ AML1 þ than in the 278 TEL/AML1À cases (52/94 (55%) vs 17/ 278 (6%); Po0.001). Neither the clinical or laboratory features at diagnosis nor early response to therapy differed significantly between TEL/AML1 þ patients with and without a TEL deletion. However, univariate analysis indicated a statistically significant worse outcome for patients with a deletion (5-year EFS: 8476 vs 9773%; P ¼ 0.034). In multivariate analysis, including sex, age and WBC count this trend was absent.
The presence of trisomy 21 was not significantly different between the TEL/AML1 þ and TEL/AML1À patients (13/94 (14%) vs 32/278 (12%); P ¼ 0.785), whereas tetrasomy 21 (1/94 (1%) vs 81/278 (29%); Po0.001) and pentasomy 21 (0/94 vs 12/ 278 (4%); P ¼ 0.029) were virtually always associated with TEL/ AML1À cases. AML1 gene amplifications were detected in three of the 278 TEL/AML1À patients. Of interest, 52 (64%) TEL/ AML1À patients with tetrasomy 21 had a high hyperdiploid karyotype, 12 (15%) had other karyotype abnormalities, while no cytogenetic information was available in the remaining 17 patients (21%). There were no significant differences between TEL/AML1 þ patients with and without a trisomy 21 with respect to the presenting features and treatment outcome. However, none of the patients with trisomy 21 coexpressed myeloid markers (P ¼ 0.023).
A duplication of the der(21)t(12;21) was evident in 14/94 (15%) TEL/AML1 þ cases. Blast cells with an extra der(21)t(12;21) were more likely to express myeloid antigens (P ¼ 0.011), while other presenting clinical and laboratory features as well as early response to treatment and outcome did not differ significantly between patients with and without an extra der(21)t(12;21).
Furthermore, although all patients without any FISH-detectable additional changes (25/94 (27%)) survived event free, their outcome was not statistically better than that of the patients with any secondary abnormality (69/94 (73%); 5-year EFS: 8675%; P ¼ 0.064). In all, 11/94 patients (12%) had more than one secondary abnormality, including each five patients with a TEL deletion/ þ 21 and four with a TEL deletion/ þ der(21) combination and each one patient with two extra normal and two extra derivative chromosomes 21.
Finally, we also determined the proportion of subclones in all three subgroups and found that a TEL deletion (range 30-100%; median 94%) was virtually present in all TEL/AML1 þ cells, whereas an extra der(21) (range 16-100%; median 85%) and an extra chromosome 21 (17-100%; median 57%) were seen in only a smaller proportion of the TEL/AML1 þ cells.
Interphase FISH of the relapsed TEL/AML1 þ patients
We were able to compare the TEL/AML1 FISH patterns of the diagnostic and relapse clone in eight of nine patients (Table 2) , two of which had been described previously. 37, 38 In two patients, the respective FISH patterns remained identical, which indicated a genuine reoccurrence of the original leukemic clone. In six patients, on the other hand, the distribution of the secondary abnormalities was different in the diagnostic and relapse samples.
Of particular interest is one patient who had multiple TEL/ AML1 þ and TEL/AML1À cell clones (Table 2, case 9). At diagnosis, a TEL deletion was seen in nine of 13 TEL/AML1À metaphases. A TEL/AML1 fusion was present in 81% of the 80 analyzable interphase cells. The following percentages always refer to the whole number of analyzed interphase cells. The 19% TEL/AML1À cells comprised 3.8% cells with a TEL deletion together with an additional AML1 signal, whereas 7.6% had none of these changes. Another 7.6% had two additional AML1 signals, but no TEL deletion. The TEL/AML1 þ cell population, on the other hand, consisted of 31% with and 50% without a TEL deletion. The former comprised 23% with two and 7.6% with three and the latter 3.8% with one, 31% with two and 15.3% with three extra AML1 signals.
In the relapse sample we were able to screen 130 cell nuclei, 48% of which were TEL/AML1À and 15% TEL/AML1À, but TEL deleted. The 37% TEL/AML1 þ cells included 7% with a TEL deletion only, 10% with a TEL deletion and two extra AML1 signals and 20% without a TEL deletion, but with one extra AML1 signal. In summary, these findings prove that all TEL/ AML1À and TEL/AML1 þ clones were also present in the relapse sample, albeit with a different size distribution. In line with a previous report describing a similar case with leukemic TEL/AML1 þ and TEL/AML1À cell populations, which shared an identical immunoglobulin gene rearrangement, this clonal heterogeneity indicates that the TEL/AML1 gene rearrangement most likely took place only after the initiating event of transformation. 39 
Discussion
Our compilation of 94 cases with a TEL/AML1 þ BCP ALL represents the third largest patient cohort reported to date, but by far the largest one that was ascertained by means of FISH analysis. [11] [12] [13] 17, 32, 33 Our findings illustrated the manifold advantages of screening with TEL-and AML1-specific FISH probes. In addition to the simple delineation of TEL/AML1 þ ALL itself, this approach particularly enables the simultaneous identification and quantification of the most common secondary karyotype abnormalities, which comprise the TEL deletion as well as the duplication of the der (21) and the acquisition of an extra chromosome 21.
So far, such FISH patterns have been successfully exploited for the investigation of the clonal origin of relapses in TEL/AML1 þ leukemia. 37, 38 As an added bonus, this technology also provides relevant information about a variety of genetic lesions that characterize several other important TEL/AML1À leukemia subgroups such as those with TEL deletions, AML1 gene amplifications and high hyperdiploid karyotypes, which are hardly retrievable on a routine basis with any other procedure or not visible without adequate metaphase preparations. 21, 22, 32, 40, 41 The 25% incidence rate of TEL/AML1 þ cases in our study is in the upper range of the 18-26% reported in RT-PCR screening surveys. [3] [4] [5] [6] [9] [10] [11] [12] [13] In line with most of these reports, patients included in our analysis also presented with well-known good prognostic features at initial diagnosis. However, the prognostic relevance of TEL/AML1 itself is still controversial and though the majority of therapy studies still reports on an extraordinary good prognosis of TEL/AML1 þ patients, interestingly, those trials with large sample sizes and an adequate long-term follow-up found similar incidence rates of TEL/AML1 þ cases at initial diagnosis and relapse. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] We showed that with an excellent 90% 5-year EFS estimate, TEL/AML1 þ patients fared significantly better than TEL/AML1À patients, and that with an incidence of 14% among the relapsed BCP ALL study population, the prevalence rate of TEL/AML1 was clearly inferior as compared to the time point of primary diagnosis.
The proportion of patients with a rapid early response to therapy in peripheral blood as well as BM was also significantly higher among the TEL/AML1 þ patients, indicating a higher sensitivity of TEL/AML1 þ blast cells to corticosteroids and a four-drug induction therapy (prednisone, vincristine, daunorubicin, L-asparaginase). Uckun et al 12 similarly reported that TEL/ AML1 þ patients responded more rapidly (M1 or M2 BM on day 7) to a three-drug induction therapy including prednisone, vincristine and L-asparaginase. In vitro drug resistance studies, however, showed that TEL/AML1 þ leukemias were only highly sensitive for L-asparaginase, but not for the other drugs tested, as compared to TEL/AML1À leukemic cells. 18 Deletions of the short arm of chromosome 12 have been well recognized as a characteristic and favorable cytogenetic feature in childhood ALL, especially for the pseudodiploid leukemic subgroup. 42 Following the identification of the TEL/AML1 gene rearrangement, it soon became clear that many of the deletions are often just secondary changes in these particular cases. 21, 22, 40, 42, 43 Moreover, it was found that they virtually always concur with the loss of the nontranslocated TEL allele. 40, 42, 43 Despite the fact that the TEL deletion may affect a variable proportion of TEL/AML1 rearranged cells, it is still considered as one of the most important cofactors to the development of overt leukemia. 21, 40, 42, 43 Accordingly, we detected a TEL deletion in 55% of the TEL/AML1 þ cases and found that it affected almost the entire TEL/AML1 þ blast cell population. However, as the particular TEL probe used was quite large, a number of small deletions may have been eventually missed. 25, 44 Of particular interest is also the intriguing observation that the gene expression profiles of TEL-deleted TEL/AML1À cases closely resemble those of TEL/AML1 þ cases, indicating that the important common designator of both diseases is the impairment of the TEL gene, be it in a mono-or biallelic manner. 45 Two hypotheses aim to explain the frequent biallelic disruption of the TEL gene. On the one hand, the wild-type TEL allele may function as a tumor suppressor gene and may be inactivated by the TEL/AML1 fusion protein through an HLHmediated homodimerization, and on the other, a normal TEL protein may trap and thus inhibit the function of the fusion protein, so that the deletion of the normal TEL allele may be Table 2 Comparison of secondary abnormalities in the diagnostic and relapse samples of nine TEL/AML1+ patients (FISH data) The proposed consequences of such TEL deletions, especially in combination with a TEL/AML1 rearrangement, would therefore imply that such deletions could provide the affected cells with a major proliferative and selective advantage. Although this question has so far not been systematically studied in TEL/AML1 þ leukemia, Kempski et al 28 did not find any difference in EFS between TEL-deleted (n ¼ 17) and non-TEL-deleted patients (n ¼ 5). In contrast and based on a much larger number of patients, we found that TEL/AML1 þ patients with a TEL deletion seem to fare actually worse than those without it. These observations suggest that, at least in TEL/AML1 þ leukemia, the type and pattern of secondary abnormalities may render the respective cell populations more resistant or sensitive to certain therapeutic measures.
Patient Diagnosis Relapse
Owing to the inability to distinguish a normal chromosome 21 from a der(21)t(12;21) with conventional cytogenetic means alone, the hitherto available incidence rates of trisomy 21 have certainly been over and those of the der(21) underestimated. 26 The possibility to differentiate clearly between these two markers with FISH, together with the prospect to evaluate their distribution and incidence also in interphase cells, drastically improves their detection rate. 12, 27 We found that in contrast to the subclones with a TEL deletion, the proportion of TEL/ AML1 þ cells with an extra chromosome 21 and duplicated der(21) was comparatively smaller.
Based on their results of metaphase FISH analyses, Fears et al 23 and Loncarevic et al 26 speculated that a duplication of the der(21) may indicate a poor prognosis, because all patients with a relapse had an extra der(21)t(12;21). Although four of our eight relapse cases also had an extra der(21), the outcome of the patients with and without an additional der(21)t(12;21) at initial diagnosis was not statistically different. This discrepancy, however, may be related to the small number of patients included in our analyses.
Individuals with a constitutional trisomy 21 have a highly increased risk to develop various types of leukemia. It was therefore surprising that previous studies reported a significantly lower incidence of TEL/AML1 þ leukemia in these patients. 12, 26, 47 However, this is not the case in our cohort of patients, because two of the eight Down syndrome patients analyzed had a TEL/AML1 rearrangement, which concords with the expected overall frequency of this specific abnormality in childhood ALL.
Finally, we also found that the distribution of diploid, pseudodiploid, hypodiploid, low hyperdiploid and near triploid karyotypes, as well as chromosome 9 and 11q23 abnormalities was similar in the TEL/AML1À and TEL/AML1 þ groups. In particular, we were unable to confirm previous suggestions that del(6q) is more common in TEL/AML1 þ cases. 12, 27 Interestingly, three of the four ALL patients with near tetraploidy were TEL/AML1 þ and remained in continuous CR. However, owing to the small number of cases, the prognostic relevance of near tetraploidy, which is usually reported to have a dismal outcome, in this context remains unclear.
Conclusively, we found that screening with TEL-and AML1-specific FISH probes generates a wealth of information about relevant, leukemia-associated specific primary and secondary genetic changes in childhood BCP ALL, which at present is in this form not attainable with any other technology. The resulting FISH patterns may provide an essential basis for further comparative analyses, for example, with the results of gene expression profiling, which will help to further clarify and delineate their particular role in the transformation process. However, a prospective systematic analysis and evaluation of the respective patterns in ongoing treatment studies may eventually also help to refine risk stratification and thereby contribute to the adaptation and individualization of therapy, particularly in TEL/AML1 þ ALL cases.
